Literature DB >> 12097418

Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus.

Peter Gergely1, Brian Niland, Nick Gonchoroff, Rudolf Pullmann, Paul E Phillips, Andras Perl.   

Abstract

Abnormal death signaling in lymphocytes of systemic lupus erythematosus (SLE) patients has been associated with elevation of the mitochondrial transmembrane potential (Delta psi(m)) and increased production of reactive oxygen intermediates (ROI). The resultant ATP depletion sensitizes T cells for necrosis that may significantly contribute to inflammation in patients with SLE. In the present study, the role of mitochondrial signal processing in T cell activation was investigated. CD3/CD28 costimulation of PBL elicited transient mitochondrial hyperpolarization and intracellular pH (pH(i)) elevation, followed by increased ROI production. Baseline Delta psi(m), ROI production, and pH(i) were elevated, while T cell activation-induced changes were blunted in 15 patients with SLE in comparison with 10 healthy donors and 10 rheumatoid arthritis patients. Similar to CD3/CD28 costimulation, treatment of control PBL with IL-3, IL-10, TGF-beta(1), and IFN-gamma led to transient Delta psi(m) elevation. IL-10 had diametrically opposing effects on mitochondrial signaling in lupus and control donors. Unlike healthy or rheumatoid arthritis PBL, cells of lupus patients were resistant to IL-10-induced mitochondrial hyperpolarization. By contrast, IL-10 enhanced ROI production and cell death in lupus PBL without affecting ROI levels and survival of control PBL. Ab-mediated IL-10 blockade or stimulation with antagonistic lymphokine IL-12 normalized baseline and CD3/CD28-induced changes in ROI production and pH(i) with no impact on Delta psi(m) of lupus PBL. The results suggest that mitochondrial hyperpolarization, increased ROI production, and cytoplasmic alkalinization play crucial roles in altered IL-10 responsiveness in SLE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097418      PMCID: PMC4020441          DOI: 10.4049/jimmunol.169.2.1092

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  56 in total

Review 1.  Apoptosis in the pathogenesis and treatment of disease.

Authors:  C B Thompson
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

2.  Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus.

Authors:  L Llorente; Y Richaud-Patin; J Wijdenes; J Alcocer-Varela; M C Maillot; I Durand-Gasselin; B M Fourrier; P Galanaud; D Emilie
Journal:  Eur Cytokine Netw       Date:  1993 Nov-Dec       Impact factor: 2.737

3.  Protective effect of N-acetylcysteine in tumor necrosis factor-alpha-induced apoptosis in U937 cells: the role of mitochondria.

Authors:  A Cossarizza; C Franceschi; D Monti; S Salvioli; E Bellesia; R Rivabene; L Biondo; G Rainaldi; A Tinari; W Malorni
Journal:  Exp Cell Res       Date:  1995-09       Impact factor: 3.905

Review 4.  Apoptosis in SLE--too little or too much?

Authors:  K B Elkon
Journal:  Clin Exp Rheumatol       Date:  1994 Sep-Oct       Impact factor: 4.473

Review 5.  Antioxidant and redox regulation of gene transcription.

Authors:  C K Sen; L Packer
Journal:  FASEB J       Date:  1996-05       Impact factor: 5.191

6.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V.

Authors:  I Vermes; C Haanen; H Steffens-Nakken; C Reutelingsperger
Journal:  J Immunol Methods       Date:  1995-07-17       Impact factor: 2.303

7.  Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl.

Authors:  S J Martin; C P Reutelingsperger; A J McGahon; J A Rader; R C van Schie; D M LaFace; D R Green
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

8.  IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase.

Authors:  M Los; H Schenk; K Hexel; P A Baeuerle; W Dröge; K Schulze-Osthoff
Journal:  EMBO J       Date:  1995-08-01       Impact factor: 11.598

9.  Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes.

Authors:  L A Casciola-Rosen; G Anhalt; A Rosen
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

10.  Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus.

Authors:  L Llorente; W Zou; Y Levy; Y Richaud-Patin; J Wijdenes; J Alcocer-Varela; B Morel-Fourrier; J C Brouet; D Alarcon-Segovia; P Galanaud; D Emilie
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more
  63 in total

Review 1.  T cells as therapeutic targets in SLE.

Authors:  José C Crispín; Vasileios C Kyttaris; Cox Terhorst; George C Tsokos
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

Review 2.  New insights into the pathogenesis of systemic lupus erythematosus.

Authors:  Vasileios C Kyttaris; Christina G Katsiari; Yuang-Taung Juang; George C Tsokos
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

3.  Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma.

Authors:  Francesca Cerimele; Traci Battle; Rebecca Lynch; David A Frank; Emma Murad; Cynthia Cohen; Nada Macaron; John Sixbey; Kenneth Smith; Randolph S Watnick; Aristidis Eliopoulos; Bahig Shehata; Jack L Arbiser
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

Review 4.  Mitochondrial membrane potential.

Authors:  Ljubava D Zorova; Vasily A Popkov; Egor Y Plotnikov; Denis N Silachev; Irina B Pevzner; Stanislovas S Jankauskas; Valentina A Babenko; Savva D Zorov; Anastasia V Balakireva; Magdalena Juhaszova; Steven J Sollott; Dmitry B Zorov
Journal:  Anal Biochem       Date:  2017-07-12       Impact factor: 3.365

Review 5.  Oxidative Modifications in Tissue Pathology and Autoimmune Disease.

Authors:  Mei-Ling Yang; Hester A Doyle; Steven G Clarke; Kevan C Herold; Mark J Mamula
Journal:  Antioxid Redox Signal       Date:  2017-12-11       Impact factor: 8.401

6.  Endoplasmic reticulum stress sensor IRE1α propels neutrophil hyperactivity in lupus.

Authors:  Gautam Sule; Basel H Abuaita; Paul A Steffes; Andrew T Fernandes; Shanea K Estes; Craig Dobry; Deepika Pandian; Johann E Gudjonsson; J Michelle Kahlenberg; Mary X O'Riordan; Jason S Knight
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 14.808

7.  Altered mitochondrial membrane potential, mass, and morphology in the mononuclear cells of humans with type 2 diabetes.

Authors:  Michael E Widlansky; Jingli Wang; Sherene M Shenouda; Tory M Hagen; Anthony R Smith; Tinoy J Kizhakekuttu; Matthew A Kluge; Dorothee Weihrauch; David D Gutterman; Joseph A Vita
Journal:  Transl Res       Date:  2010-05-11       Impact factor: 7.012

Review 8.  Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment.

Authors:  Andras Perl
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

Review 9.  The biology of reactive intermediates in systemic lupus erythematosus.

Authors:  Jim C Oates
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

10.  CD3+ICOS+ T cells show differences in the synthesis of nitric oxide, IFN-γ, and IL-10 in patients with pulmonary tuberculosis or in healthy household contacts.

Authors:  Carmen Lara-Rodríguez; Noé Alvarado-Vásquez; Demetrio Bernal; Patricia Gorocica; Edgar Zenteno; Ricardo Lascuraín
Journal:  Clin Exp Med       Date:  2015-08-08       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.